BE of parenterals [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2018-10-08 09:53 (880 d 13:51 ago) – Posting: # 19416
Views: 2,460

Hi Varsha,

» As per guideline we need not to perform any Bioequivalence studies for Injectables.

It’s not that simple. See e.g., the EMA’s GL page 23.

» But Enoxaparin sodium being a biologically derived product, is there any need of performing the BA-BE studies.

That’s not the point. See the FDA’s guidance for conditions whether the in vivo PD (!) study can be waived.

» Does the guideline differs for a biologically derived product?

Differ to what? To get an idea, see the EMA’s guidelines on biosimilars.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,371 posts in 4,463 threads, 1,495 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Saturday 23:45 UTC (Europe/Vienna)

When people learn no tools of judgment
and merely follow their hopes,
the seeds of political manipulation are sown.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5